ITCI - Intra-Cellular Therapies, Inc.
IEX Last Trade
85.31
10.540 12.355%
Share volume: 0
Last Updated: Tue 24 Dec 2024 05:59:53 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
19.80%
PREVIOUS CLOSE
CHG
CHG%
$74.77
10.54
14.10%
Fundamental analysis
28%
Profitability
25%
Dept financing
4%
Liquidity
75%
Performance
25%
Performance
5 Days
2.14%
1 Month
0.29%
3 Months
14.62%
6 Months
17.70%
1 Year
21.17%
2 Year
68.33%
Key data
Stock price
$85.31
DAY RANGE
$74.77 - $83.89
52 WEEK RANGE
$65.09 - $93.45
52 WEEK CHANGE
$15.74
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: Sharon Mates
Region: US
Website: intracellulartherapies.com
Employees: 560
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: intracellulartherapies.com
Employees: 560
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Intra-Cellular Therapies, Inc. develops novel drugs for the treatment of neuropsychiatric and neurologic diseases. The company offers CAPLYTA for schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for bipolar depression, as well as to treat autism spectrum disorder.
Recent news